Daniel Chang
このコンテンツはまだ日本語訳がありません。
Daniel Chang is a Hugel Korea leadership figure in Hugel’s current global structure. His role is relevant to Korea operations, company continuity around Botulax and Letybo, and the company’s global medical-aesthetics expansion.
Chang’s page complements Carrie Strom, Hugel’s President and Global Chief Executive Officer. Strom connects Hugel to global aesthetic commercialization experience, while Chang anchors the Korean company context that sits behind Botulax and Letybo.
Role Context
Section titled “Role Context”| Field | Detail |
|---|---|
| Current organization | Hugel |
| Current role | Head of Hugel Korea, as described in Hugel’s October 2025 CEO appointment announcement |
| Industry relevance | Hugel Korea leadership for Botulax / Letybo global expansion |
| Relevant company | Hugel |
| Relevant brand | Letybo |
| Market context | Korea-origin toxin manufacturing and expansion into the United States, Europe, China, and other markets |
Career Notes
Section titled “Career Notes”- Hugel’s official English about page identifies Daniel Chang in its CEO message, while Hugel’s October 2025 appointment announcement describes him as the recently appointed head of Hugel Korea reporting into Carrie Strom’s global CEO structure.
- Hugel describes itself as the first South Korean botulinum toxin company to have entered the United States, Europe, and China.
- Hugel’s R&D materials identify HG 101 as Botulax and list Korean approval milestones from 2010 onward.
- Letybo’s U.S. prescribing information identifies the product as letibotulinumtoxinA-wlbg and preserves product-specific unit and indication limits.
Global Expansion Context
Section titled “Global Expansion Context”Chang matters because Hugel’s toxin story is a Korea-origin manufacturing and market-entry story as much as a product-identity story. Botulax anchors Korean and export-associated identity, while Letybo provides the current U.S. label anchor.
That global visibility should not be overread. Botulax, Letybo, and other Hugel-associated regional names may be related, but local labels, approved indications, vial presentations, commercial partners, and unit systems remain market-specific.
Activity and Public Context
Section titled “Activity and Public Context”Chang’s Hugel and Letybo relevance is Korean company background around global expansion. Clinical and regulatory claims should stay tied to Letybo prescribing information and local approval sources.